Alector downgraded to Neutral from Buy at BofA

BofA analyst Greg Harrison downgraded Alector to Neutral from Buy with a price target of $12, down from $24. Based on what he sees as "the slow but steady movement in clinical development" he thinks Alector could be validated in the future, but sees other companies with more favorable risk/reward profiles in his coverage, Harrison tells investors.